Compare Alcon AG (ALC) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Impinj Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Impinj Inc trades at $142.9 (market cap $4.20B). The key difference: Alcon AG is far larger — about 7.8× Impinj Inc's market cap, and Alcon AG pays a 0.54% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| ALC | PI | |
|---|---|---|
Market Cap | $32.69B | $4.20B |
Sector | Health | Technology |
52-Week High | $92.22 | $241.91 |
52-Week Low | $62.02 | $91.34 |
Enterprise Value | $36.28B | $4.34B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Impinj (PI) trades at $148.00, up 4.53% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $167.50. Recent Q1 2026 earnings beat expectations, but the company shows negative net income margins and elevated valuation multiples. Key news includes upcoming Q2 2026 results and insider selling activity.
The stock offers upside potential from strong analyst buy ratings and RFID technology leadership, but risks include persistent profitability challenges, high debt-to-asset ratio (51.52% in 2025), and sensitivity to earnings misses. Investor sentiment is mixed amid growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
